Snake envenomation during pregnancy is an uncommon emergency with several potential complications associated with the poisoning and its treatment. This case discusses a 27-y-old gravida 3, para 1102 (3 total pregnancies, 1 term birth, 1 premature birth, 0 abortions, 2 living births, twins) at 36 wk gestation who was bitten by a presumed Agkistrodon contortrix (copperhead snake). She had worsening pain and swelling in the right lower limb. Crotalidae polyvalent immune Fab was administered. The patient felt significantly better with improvement in swelling. She had a reactive nonstress test and reassuring coagulation studies. She gave birth to a healthy female infant 12 d later. This case supports the use of Crotalidae polyvalent immune Fab for venomous snakebites in pregnant patients to prevent possible maternal and fetal morbidity and mortality.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.wem.2019.06.015 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Antivenom Administration After Rattlesnake Envenoming in Arizona Does Not Directly Diminish Pain.
Toxins (Basel)
December 2024
Poison Control Center, The University of Arizona College of Pharmacy, Tucson, AZ 85724, USA.
The onset, progression, and severity of pain following rattlesnake envenomation are highly variable between patients. Pain can be severe and persistent, seemingly refractory to opioid analgesics. The ability of antivenom to directly relieve pain has not been well studied.
View Article and Find Full Text PDFWestern Pygmy Rattlesnake Envenomation and Bite Management.
Cutis
October 2024
Department of Orthopaedic Surgery, University of Illinois Chicago.
Article Synopsis
- The western pygmy rattlesnake is a small but dangerous snake native to several U.S. states, including Missouri and Tennessee.
- Bites from this snake can lead to serious health issues like hospitalization and tissue damage.
- A case study highlights a 56-year-old man who was bitten and required antivenom treatment and prolonged wound care.
Acute adverse effects of F(ab')₂AV and FabAV use for rattlesnake Envenomations: A four-year poison center study.
Am J Emerg Med
January 2025
Department of Emergency Medicine, UC San Diego Health, San Diego, CA, USA; San Diego Division, California Poison Control System, San Diego, CA, USA.
Article Synopsis
- Rattlesnake envenomations are common in the U.S., with two main antivenoms available: CroFab® and ANAVIP®.
- A study reviewed 481 cases of rattlesnake bites treated with these antivenoms between 2018 and 2022, focusing on adverse effects.
- Results show that CroFab® had a higher rate of severe adverse events (1.5%) compared to ANAVIP®, which had none, indicating that both antivenoms are generally safe but ANAVIP® may have a better safety profile.
Article Synopsis
- This study compared the effectiveness and safety of two FDA-approved antivenoms, FabAV (Crotalidae polyvalent immune fab) and Fab2AV (Crotalidae immune F(ab')) for treating eastern copperhead bites.
- Of the 134 patients analyzed, 89 received antivenom, with FabAV achieving 100% initial control compared to 89.8% for Fab2AV, while FabAV required fewer doses (median of 6 vials) than Fab2AV (median of 10 vials).
- Additionally, patients treated with Fab2AV experienced acute adverse reactions at a higher rate (11.9%) compared to none for FabAV.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!